Genetic imbalance related to cisplatin-based chemoresistance in epithelial ovarian cancer

被引：0

作者：

Huanchun, Y. ^{[1
]}

Shulan, Z. ^{[1
]}

Jing, L. ^{[2
]}

机构：

[1] China Med Univ, Shengjing Hosp, Dept Gynecol & Obstet, Shenyang 110004, Liaoning Prov, Peoples R China

[2] Fifth Hosp Shenyang, Dept Oncol, Shenyang, Peoples R China

来源：

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2009年 / 30卷 / 02期

关键词：

Epithelial ovarian cancer; Drug-resistant; Comparative Genomic hybridization (CGH); COMPARATIVE GENOMIC HYBRIDIZATION; RESISTANCE; CARCINOMA; OVEREXPRESSION; CHEMOTHERAPY; APOPTOSIS; LYMPHOMA; REVEALS;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of investigation: To identify genetic imbalance related to chemoresistance in epithelial ovarian cancer. Methods: We screened abnormal chromosomal regions in cisplatin-resistant and cisplatin-sensitive human ovarian cancer cell lines employing comparative genomic hybridization (CGH). We also documented non-random chromosome gains and losses with cisplatin-resistant and cisplatin-sensitive primary epithelial ovarian tumors from patients. Results: There were extensive chromosome changes in cisplatin-resistant and cisplatin-sensitive cell lines. Gains of 1q12-22. 17q21-22 and loss of 3p21-24 were significantly more common in drug-resistant tumors from patients compared to the drug-sensitive group. Conclusions: The special chromosomal aberrances might provide LIS With a Clue for further investigation of the dominant mechanism that leads to a drug-resistant phenotype.

引用

页码：181 / 185

页数：5

共 22 条

[1]

Boulikas T, 2003, ONCOL REP, V10, P1663

[2] Chemotherapy resistance in ovarian cancer: New molecular perspectives [J].

Coukos, G ;

Rubin, SC .

OBSTETRICS AND GYNECOLOGY, 1998, 91 (05) :783-792

[3] T-bet, a T cell-associated transcription factor, is expressed in Hodgkin's lymphoma [J].

Dorfman, DM ;

Hwang, ES ;

Shahsafaei, A ;

Glimcher, LH .

HUMAN PATHOLOGY, 2005, 36 (01) :10-15

[4] Genome screening by comparative genomic hybridization [J].

Forozan, F ;

Karhu, R ;

Kononen, J ;

Kallioniemi, A ;

Kallioniemi, OP .

TRENDS IN GENETICS, 1997, 13 (10) :405-409

[5] Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer [J].

Gotlieb, WH ;

Goldberg, I ;

Weisz, B ;

Davidson, B ;

Novikov, I ;

Kopolovic, J ;

Ben-Baruch, G .

GYNECOLOGIC ONCOLOGY, 2001, 82 (01) :99-104

[6] Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization [J].

Hauptmann, S ;

Denkert, C ;

Koch, I ;

Petersen, S ;

Schlüns, K ;

Reles, A ;

Dietel, M ;

Petersen, I .

HUMAN PATHOLOGY, 2002, 33 (06) :632-641

[7] Variation in RNA expression and genomic DNA content acquired during cell culture [J].

Hiorns, LR ;

Bradshaw, TD ;

Skelton, LA ;

Yu, Q ;

Kelland, LR ;

Leyland-Jones, B .

BRITISH JOURNAL OF CANCER, 2004, 90 (02) :476-482

[8] Comparative study of primary and recurrent ovarian serous carcinomas: comparative genomic hybridization analysis with a potential application for prognosis [J].

Hu, J ;

Khanna, V ;

Jones, MW ;

Surti, U .

GYNECOLOGIC ONCOLOGY, 2003, 89 (03) :369-375

[9]

Karpova MB, 2006, INT J ONCOL, V28, P605

[10] Alterations in the apoptotic machinery and their potential role in anticancer drug resistance [J].

Kaufmann, SH ;

Vaux, DL .

ONCOGENE, 2003, 22 (47) :7414-7430

← 1 2 3 →